COL4A5_HUMAN,G380D,0.952,Gain of Loop (Pr = 0.27 | P = 0.02), ELME000155,-
COL4A5_HUMAN,G362R,0.941,Altered Disordered interface (Pr = 0.28 | P = 0.03); Gain of Acetylation at K358 (Pr = 0.28 | P = 4.9e-03); Loss of Methylation at K358 (Pr = 0.18 | P = 9.9e-03); Gain of SUMOylation at K358 (Pr = 0.18 | P = 0.05), ELME000155,-
COL4A5_HUMAN,P619L,0.295,-,-,-
COL4A5_HUMAN,G887R,0.947,Loss of Loop (Pr = 0.30 | P = 6.6e-03); Gain of Acetylation at K885 (Pr = 0.25 | P = 0.01); Loss of Methylation at K885 (Pr = 0.21 | P = 5.6e-03); Gain of SUMOylation at K885 (Pr = 0.19 | P = 0.04); Loss of Ubiquitylation at K885 (Pr = 0.16 | P = 0.04), ELME000062|ELME000239,-
COL4A5_HUMAN,G914D,0.964,, ELME000085|ELME000097|ELME000239,-
COL4A5_HUMAN,G472R,0.946,Loss of Loop (Pr = 0.29 | P = 0.01), None,-
COL4A5_HUMAN,G325E,0.939,Altered Disordered interface (Pr = 0.27 | P = 0.04); Loss of Acetylation at K330 (Pr = 0.27 | P = 7.4e-03); Loss of Phosphorylation at Y320 (Pr = 0.27 | P = 0.03); Loss of Methylation at K330 (Pr = 0.24 | P = 2.5e-03); Gain of SUMOylation at K330 (Pr = 0.21 | P = 0.03); Gain of Sulfation at Y320 (Pr = 0.04 | P = 9.3e-03), ELME000006,-
COL4A5_HUMAN,G536C,0.950,Loss of B-factor (Pr = 0.27 | P = 0.02), ELME000155,-
COL4A5_HUMAN,G609D,0.953,Gain of Loop (Pr = 0.30 | P = 4.5e-03); Altered Disordered interface (Pr = 0.27 | P = 0.05); Loss of B-factor (Pr = 0.26 | P = 0.04), None,-
COL4A5_HUMAN,G1348R,0.950,Loss of B-factor (Pr = 0.29 | P = 0.01), ELME000149,-
COL4A5_HUMAN,G403V,0.961,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Acetylation at K408 (Pr = 0.20 | P = 0.04); Loss of Methylation at K408 (Pr = 0.19 | P = 7.8e-03); Loss of SUMOylation at K408 (Pr = 0.19 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q407 (Pr = 0.06 | P = 0.03), None,-
COL4A5_HUMAN,G638V,0.960,Loss of Acetylation at K634 (Pr = 0.28 | P = 6.1e-03); Loss of Methylation at K634 (Pr = 0.20 | P = 7.2e-03), None,-
COL4A5_HUMAN,G545R,0.943,Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of SUMOylation at K544 (Pr = 0.29 | P = 3.5e-03); Loss of Methylation at K544 (Pr = 0.20 | P = 6.9e-03); Loss of Ubiquitylation at K544 (Pr = 0.16 | P = 0.04); Loss of Proteolytic cleavage at D549 (Pr = 0.13 | P = 0.03), ELME000064|ELME000100|ELME000108|PS00005|PS00006,-
COL4A5_HUMAN,M898V,0.196,-,-,-
COL4A5_HUMAN,G216V,0.946,Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of Loop (Pr = 0.26 | P = 0.05); Loss of Methylation at K215 (Pr = 0.21 | P = 5.7e-03); Gain of SUMOylation at K215 (Pr = 0.20 | P = 0.03), None,-
COL4A5_HUMAN,G530D,0.942,Loss of Methylation at K526 (Pr = 0.23 | P = 3.6e-03); Loss of Acetylation at K526 (Pr = 0.20 | P = 0.04); Gain of Ubiquitylation at K526 (Pr = 0.15 | P = 0.05), ELME000005|ELME000155,-
COL4A5_HUMAN,P649A,0.290,-,-,-
COL4A5_HUMAN,G1164D,0.950,Loss of B-factor (Pr = 0.27 | P = 0.03); Loss of Methylation at K1168 (Pr = 0.24 | P = 2.5e-03); Loss of Acetylation at K1166 (Pr = 0.22 | P = 0.03); Loss of SUMOylation at K1166 (Pr = 0.20 | P = 0.03), None,-
COL4A5_HUMAN,G524D,0.927,Loss of Methylation at K526 (Pr = 0.23 | P = 3.6e-03); Gain of Acetylation at K526 (Pr = 0.20 | P = 0.04); Gain of Ubiquitylation at K526 (Pr = 0.16 | P = 0.04), None,-
COL4A5_HUMAN,G656R,0.883,Loss of B-factor (Pr = 0.28 | P = 0.02); Loss of Loop (Pr = 0.27 | P = 0.05); Loss of Methylation at K652 (Pr = 0.25 | P = 1.9e-03); Gain of O-linked glycosylation at T660 (Pr = 0.15 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q657 (Pr = 0.06 | P = 0.03), ELME000062|PS00008,-
COL4A5_HUMAN,G763V,0.948,Loss of B-factor (Pr = 0.34 | P = 2.2e-03); Altered Disordered interface (Pr = 0.30 | P = 0.03); Loss of Acetylation at K768 (Pr = 0.25 | P = 0.01); Loss of SUMOylation at K768 (Pr = 0.18 | P = 0.05); Loss of Methylation at K768 (Pr = 0.17 | P = 0.01), None,-
COL4A5_HUMAN,G629D,0.896,Loss of Acetylation at K634 (Pr = 0.27 | P = 6.7e-03); Loss of Methylation at K634 (Pr = 0.20 | P = 6.3e-03), ELME000155,-
COL4A5_HUMAN,G406S,0.932,Gain of Acetylation at K408 (Pr = 0.19 | P = 0.04); Loss of Methylation at K408 (Pr = 0.19 | P = 8.0e-03); Loss of SUMOylation at K408 (Pr = 0.19 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q407 (Pr = 0.05 | P = 0.03), ELME000202|PS00005,-
COL4A5_HUMAN,G195V,0.946,Loss of B-factor (Pr = 0.32 | P = 4.2e-03); Altered Disordered interface (Pr = 0.27 | P = 0.04), ELME000155,-
COL4A5_HUMAN,C1638G,0.950,Altered Metal binding (Pr = 0.65 | P = 1.4e-03); Loss of Disulfide linkage at C1638 (Pr = 0.36 | P = 6.8e-04); Altered Ordered interface (Pr = 0.34 | P = 6.2e-03); Altered Transmembrane protein (Pr = 0.28 | P = 3.6e-04), ELME000062|ELME000162|PS00008,-
COL4A5_HUMAN,G787V,0.955,Loss of B-factor (Pr = 0.33 | P = 3.0e-03), ELME000006|ELME000220|ELME000231,-
COL4A5_HUMAN,G576S,0.948,, ELME000136|ELME000155|ELME000159|ELME000358,-
COL4A5_HUMAN,G186S,0.909,Altered Disordered interface (Pr = 0.28 | P = 0.03); Gain of O-linked glycosylation at T188 (Pr = 0.23 | P = 0.01), ELME000136|ELME000159,-
COL4A5_HUMAN,G802V,0.946,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of Acetylation at K798 (Pr = 0.19 | P = 0.05); Loss of Methylation at K798 (Pr = 0.18 | P = 9.0e-03); Altered Metal binding (Pr = 0.10 | P = 0.05), None,-
COL4A5_HUMAN,G1214E,0.957,Altered Disordered interface (Pr = 0.27 | P = 0.04); Gain of Loop (Pr = 0.27 | P = 0.03), None,-
COL4A5_HUMAN,G869R,0.934,, None,-
COL4A5_HUMAN,G635C,0.937,Loss of Acetylation at K634 (Pr = 0.33 | P = 2.6e-03); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Methylation at K634 (Pr = 0.22 | P = 4.7e-03); Gain of SUMOylation at K634 (Pr = 0.18 | P = 0.05), None,-
COL4A5_HUMAN,G687E,0.928,Gain of Loop (Pr = 0.31 | P = 3.0e-03), ELME000155,-
COL4A5_HUMAN,G684V,0.953,Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of Loop (Pr = 0.27 | P = 0.03), ELME000155,-
COL4A5_HUMAN,G615R,0.947,Loss of Loop (Pr = 0.31 | P = 4.7e-03); Altered Disordered interface (Pr = 0.27 | P = 0.05), PS00008,-
COL4A5_HUMAN,G947D,0.946,Gain of Loop (Pr = 0.28 | P = 0.02); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of SUMOylation at K943 (Pr = 0.26 | P = 6.9e-03); Loss of Methylation at K943 (Pr = 0.24 | P = 2.5e-03); Loss of Acetylation at K943 (Pr = 0.23 | P = 0.02), ELME000005|ELME000155,-
COL4A5_HUMAN,G497C,0.941,Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of Loop (Pr = 0.29 | P = 0.01); Gain of Pyrrolidone carboxylic acid at Q495 (Pr = 0.08 | P = 0.02), None,-
COL4A5_HUMAN,G675S,0.941,Gain of Loop (Pr = 0.27 | P = 0.02); Gain of Proteolytic cleavage at D674 (Pr = 0.11 | P = 0.04), ELME000062|ELME000155,-
COL4A5_HUMAN,G772V,0.954,Altered Disordered interface (Pr = 0.30 | P = 0.02); Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Acetylation at K768 (Pr = 0.25 | P = 0.01); Gain of SUMOylation at K768 (Pr = 0.18 | P = 0.04); Loss of Methylation at K768 (Pr = 0.17 | P = 0.01), ELME000146,-
COL4A5_HUMAN,G784D,0.926,Gain of Loop (Pr = 0.27 | P = 0.03); Loss of B-factor (Pr = 0.26 | P = 0.04); Altered Metal binding (Pr = 0.10 | P = 0.05), ELME000006,-
COL4A5_HUMAN,G881R,0.958,Loss of B-factor (Pr = 0.27 | P = 0.02); Gain of Acetylation at K885 (Pr = 0.27 | P = 6.8e-03); Loss of Methylation at K885 (Pr = 0.21 | P = 5.4e-03); Gain of SUMOylation at K885 (Pr = 0.18 | P = 0.05); Loss of Ubiquitylation at K885 (Pr = 0.16 | P = 0.04), ELME000006|ELME000136|ELME000155|ELME000159|PS00005,-
COL4A5_HUMAN,G96R,0.937,Loss of Loop (Pr = 0.30 | P = 6.8e-03); Altered Disordered interface (Pr = 0.28 | P = 0.04); Gain of Methylation at R92 (Pr = 0.10 | P = 0.04), ELME000005|ELME000135|ELME000155,-
COL4A5_HUMAN,G1261R,0.953,Loss of Loop (Pr = 0.32 | P = 3.4e-03); Loss of B-factor (Pr = 0.28 | P = 0.02), ELME000006|ELME000012|ELME000102|ELME000108|ELME000135|ELME000155,-
COL4A5_HUMAN,G1229D,0.960,, None,-
COL4A5_HUMAN,G600D,0.933,Gain of Loop (Pr = 0.30 | P = 5.4e-03); Loss of Acetylation at K599 (Pr = 0.27 | P = 7.1e-03); Loss of Methylation at K599 (Pr = 0.19 | P = 7.2e-03); Gain of SUMOylation at K599 (Pr = 0.19 | P = 0.04), ELME000002|ELME000220|PS00006,-
COL4A5_HUMAN,G527V,0.934,Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of Methylation at K526 (Pr = 0.23 | P = 3.2e-03); Loss of Acetylation at K526 (Pr = 0.20 | P = 0.04); Gain of SUMOylation at K526 (Pr = 0.19 | P = 0.04), ELME000005|ELME000106|ELME000155,-
COL4A5_HUMAN,G1252S,0.913,Loss of B-factor (Pr = 0.28 | P = 0.02); Gain of Loop (Pr = 0.27 | P = 0.03); Loss of Methylation at K1251 (Pr = 0.25 | P = 2.4e-03); Loss of Acetylation at K1251 (Pr = 0.23 | P = 0.02); Gain of SUMOylation at K1251 (Pr = 0.23 | P = 0.02), None,-
COL4A5_HUMAN,G558R,0.922,Loss of B-factor (Pr = 0.28 | P = 0.02); Altered Disordered interface (Pr = 0.27 | P = 0.05); Gain of SUMOylation at K560 (Pr = 0.25 | P = 7.8e-03); Gain of Acetylation at K557 (Pr = 0.21 | P = 0.03); Loss of Methylation at K557 (Pr = 0.18 | P = 9.6e-03), ELME000100|ELME000108,-
COL4A5_HUMAN,G896D,0.953,Gain of Loop (Pr = 0.29 | P = 0.01); Gain of SUMOylation at K895 (Pr = 0.26 | P = 6.9e-03); Loss of Acetylation at K895 (Pr = 0.25 | P = 0.01); Loss of Methylation at K895 (Pr = 0.19 | P = 7.4e-03), ELME000064|ELME000220|PS00006,-
COL4A5_HUMAN,G911R,0.962,Loss of B-factor (Pr = 0.27 | P = 0.03); Gain of O-linked glycosylation at S916 (Pr = 0.19 | P = 0.02), ELME000006,-
COL4A5_HUMAN,G693R,0.948,Loss of Loop (Pr = 0.27 | P = 0.03); Gain of SUMOylation at K698 (Pr = 0.25 | P = 8.2e-03); Gain of Acetylation at K698 (Pr = 0.21 | P = 0.03); Loss of Methylation at K698 (Pr = 0.18 | P = 9.6e-03), PS00008,-
COL4A5_HUMAN,G1261E,0.946,Gain of Loop (Pr = 0.35 | P = 6.0e-04); Loss of B-factor (Pr = 0.27 | P = 0.03), ELME000155,-
COL4A5_HUMAN,Q1308R,0.265,-,-,-
COL4A5_HUMAN,K664N,0.091,-,-,-
COL4A5_HUMAN,A16S,0.417,-,-,-
COL4A5_HUMAN,G35E,0.591,Gain of Loop (Pr = 0.26 | P = 0.05), ELME000063|ELME000136|ELME000159|PS00008,-
COL4A5_HUMAN,D39E,0.335,-,-,-
COL4A5_HUMAN,K47M,0.782,Loss of SUMOylation at K47 (Pr = 0.38 | P = 1.2e-03); Loss of B-factor (Pr = 0.29 | P = 0.01); Gain of Loop (Pr = 0.27 | P = 0.04); Loss of Acetylation at K44 (Pr = 0.21 | P = 0.03); Loss of Methylation at K44 (Pr = 0.12 | P = 0.03), None,-
COL4A5_HUMAN,Q143P,0.449,-,-,-
COL4A5_HUMAN,M163T,0.208,-,-,-
COL4A5_HUMAN,P185A,0.065,-,-,-
COL4A5_HUMAN,I274M,0.091,-,-,-
COL4A5_HUMAN,P278T,0.560,Loss of B-factor (Pr = 0.32 | P = 4.4e-03); Gain of O-linked glycosylation at P278 (Pr = 0.12 | P = 0.04); Loss of Methylation at R275 (Pr = 0.11 | P = 0.03), ELME000005|ELME000155,-
COL4A5_HUMAN,I355V,0.038,-,-,-
COL4A5_HUMAN,I378M,0.141,-,-,-
COL4A5_HUMAN,V392I,0.044,-,-,-
COL4A5_HUMAN,I418M,0.207,-,-,-
COL4A5_HUMAN,D425E,0.189,-,-,-
COL4A5_HUMAN,A440P,0.081,-,-,-
COL4A5_HUMAN,K477R,0.221,-,-,-
COL4A5_HUMAN,T597A,0.068,-,-,-
COL4A5_HUMAN,F598S,0.240,-,-,-
COL4A5_HUMAN,P623L,0.248,-,-,-
COL4A5_HUMAN,I648V,0.055,-,-,-
COL4A5_HUMAN,D682E,0.113,-,-,-
COL4A5_HUMAN,P738L,0.142,-,-,-
COL4A5_HUMAN,T789A,0.068,-,-,-
COL4A5_HUMAN,I818T,0.144,-,-,-
COL4A5_HUMAN,D847N,0.160,-,-,-
COL4A5_HUMAN,T894A,0.032,-,-,-
COL4A5_HUMAN,I1020E,0.172,-,-,-
COL4A5_HUMAN,T1028S,0.056,-,-,-
COL4A5_HUMAN,S1072G,0.050,-,-,-
COL4A5_HUMAN,T1126I,0.112,-,-,-
COL4A5_HUMAN,V1151I,0.042,-,-,-
COL4A5_HUMAN,Q1159P,0.114,-,-,-
COL4A5_HUMAN,P1245S,0.201,-,-,-
COL4A5_HUMAN,Q1308P,0.256,-,-,-
COL4A5_HUMAN,V1340I,0.030,-,-,-
COL4A5_HUMAN,A1375S,0.054,-,-,-
COL4A5_HUMAN,V1458T,0.231,-,-,-
COL4A5_HUMAN,M1547V,0.188,-,-,-
COL4A5_HUMAN,S1556G,0.234,-,-,-
COL4A5_HUMAN,A1565V,0.494,-,-,-
COL4A5_HUMAN,V1572M,0.079,-,-,-
COL4A5_HUMAN,G1039S,0.926,, ELME000155,-
COL4A5_HUMAN,G135D,0.967,, ELME000005|ELME000136|ELME000155|ELME000159|ELME000197,-
COL4A5_HUMAN,G564C,0.947,Loss of B-factor (Pr = 0.26 | P = 0.04); Loss of SUMOylation at K560 (Pr = 0.26 | P = 6.6e-03); Loss of Acetylation at K560 (Pr = 0.19 | P = 0.05); Loss of Methylation at K560 (Pr = 0.17 | P = 0.01), ELME000136|ELME000155|ELME000159,-
COL4A5_HUMAN,G1140R,0.964,Loss of B-factor (Pr = 0.30 | P = 8.7e-03); Altered Metal binding (Pr = 0.12 | P = 0.03); Gain of O-linked glycosylation at S1136 (Pr = 0.11 | P = 0.05), ELME000135|ELME000155,-
COL4A5_HUMAN,G337V,0.946,Loss of B-factor (Pr = 0.34 | P = 1.6e-03); Loss of Methylation at K333 (Pr = 0.25 | P = 2.4e-03); Gain of Acetylation at K333 (Pr = 0.23 | P = 0.02); Loss of SUMOylation at K333 (Pr = 0.20 | P = 0.04), ELME000155,-
